<DOC>
	<DOCNO>NCT01832415</DOCNO>
	<brief_summary>The French cooperative group GINECO propose implement observational study describe real situation , daily practice tolerance method administration bevacizumab ( Avastin ® )</brief_summary>
	<brief_title>First Line Ovarian Cancer Treatment - Cohort Study</brief_title>
	<detailed_description>Population : Patients age 18 year old epithelial ovarian cancer , fallopian tube primary peritoneal witch decide initiate process comprise Bevacizumab ( Avastin ® ) first-line therapy</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients age 18 year , Patients epithelial ovarian cancer , fallopian tube peritoneal receive bevacizumab ( Avastin ® ) firstline therapy Patients inform study orally objection data process . Patient participation clinical trial Patient nonaffiliated social security scheme .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>First line treatment</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>fallopian tube primary peritoneal</keyword>
</DOC>